European Journal of Cancer最新文献

{"title":"Surgical stage in the era of molecular profiling of endometrial cancer","authors":"J.C. Kasius ,&nbsp;W. Kildal ,&nbsp;S.W. Vrede ,&nbsp;H.A. Askautrud ,&nbsp;M. Pradhan ,&nbsp;A.M. van Altena ,&nbsp;K.-A.R. Tobin ,&nbsp;K. Knoll ,&nbsp;C. Reijnen ,&nbsp;S. Reimann ,&nbsp;G. Dackus ,&nbsp;L. Vlatkovic ,&nbsp;J. Huvila ,&nbsp;M. Steinlechner ,&nbsp;V. Tubita ,&nbsp;A. Gil-Moreno ,&nbsp;M.P.L.M. Snijders ,&nbsp;M.C. Vos ,&nbsp;T.S. Hveem ,&nbsp;J. Asberger ,&nbsp;A. Kleppe","doi":"10.1016/j.ejca.2025.116164","DOIUrl":"10.1016/j.ejca.2025.116164","url":null,"abstract":"<div><h3>Introduction</h3><div>Molecular classification has reshaped risk stratification in endometrial cancer (EC), yet the relevance of tumor spread within molecular subgroups has not been reported so far.</div></div><div><h3>Material and methods</h3><div>This multicenter retrospective study included 2056 EC patients treated between 1994 and 2018 across 11 European centers. All histopathological subtypes and FIGO stages were included. Tumors were classified into four molecular subgroups: <em>POLE</em>-mutated (<em>POLE</em>mut), mismatch repair deficient (MMRd), no specific molecular profile (NSMP), and <em>TP53/</em>p53 abnormal (p53abn). Clinical and pathological data were extracted from existing cohort databases.</div></div><div><h3>Results</h3><div>Patients were diagnosed with FIGO stage I (69 %), II (9 %), III (16 %), and IV (6 %), and classified into: <em>POLE</em>mut (8 %), MMRd (28 %), NSMP (44 %), and p53abn (21 %). The overall 5-year cancer-specific death (CSD) and recurrence rates were 16.5 % (95 % CI, 14.9 %-18.2 %) and 23.8 % (95 % CI, 22.0 %-25.7 %), respectively. In multivariable analysis cancer-specific survival (CSS) was independently associated with molecular subtype, FIGO stage, age, histopathological type, grade, lymphovascular space invasion, adjuvant therapy, residual tumor, and lymphadenectomy. FIGO stage was significantly associated with CSD also in within each molecular subgroup (p &lt; 0.001). Patients with tumors confined to the uterus had the most favourable prognosis. Lymph node metastases significantly decreased CSS in <em>POLE</em>mut, MMRd, and p53abn groups. Within FIGO stage IV, molecular subtype was not significantly related to outcome.</div></div><div><h3>Discussion</h3><div>Surgical stage remains a strong prognostic factor across molecular subtypes and should be considered alongside molecular classification when tailoring adjuvant treatment in EC.</div></div>","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"233 ","pages":"Article 116164"},"PeriodicalIF":7.1,"publicationDate":"2025-12-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145735788","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Current and emerging opportunities for deintensification of systemic therapies in melanoma: A scoping review","authors":"Jennifer A. Soon ,&nbsp;Fanny Franchini ,&nbsp;Peter Gourlay ,&nbsp;Maarten J. IJzerman ,&nbsp;Grant A. McArthur","doi":"10.1016/j.ejca.2025.116132","DOIUrl":"10.1016/j.ejca.2025.116132","url":null,"abstract":"<div><h3>Purpose</h3><div>There is growing interest in optimising melanoma management to reduce over-treatment and improve patient safety and quality-of-life, yet clinical guidance on deintensification is minimal. This scoping review characterises the role of systemic therapies and biomarkers in current and emerging melanoma deintensification strategies. Study types, funding sources, and use of patient-reported outcomes (PRO) were also summarised.</div></div><div><h3>Methods</h3><div>MEDLINE, EMBASE and PubMed searches identified studies on deintensification in adult patients with cutaneous melanoma (January 2013 to June 2023). Additional texts were sourced via Google Scholar and backward citation searches. Three extraction tools were tailored to accommodate the breadth of articles included: A) deintensification approaches including biomarkers in late-phase development; B) non-systematic reviews; and C) early-phase biomarkers. Screening and data extraction were performed by two reviewers using Covidence. Data were analysed using descriptive statistics with results reported as per PRISMA-ScR guidelines.</div></div><div><h3>Results</h3><div>Of 3721 articles screened, 301 articles were included: 31 non-systematic reviews, 198 early-phase biomarker studies, and 72 studies on deintensification approaches. Five key approaches emerged: shortened duration of therapy, dose attenuation, biomarker-informed, neoadjuvant and/or response-adapted, and miscellaneous. Most data were retrospective; only five randomised controlled trials were included in Category A (two were trial protocols). Early-phase biomarker studies comprised 66 % (n = 198/301) of articles – few progressed to trials of clinical validation/utility. PRO were reported in 11 % (n = 5/45) of Category A studies.</div></div><div><h3>Conclusions</h3><div>Shortened duration of anti-PD-1 therapy and neoadjuvant approaches hold substantial promise in deintensification. Future trials should prioritise consistent incorporation of PRO and focus on determining clinical utility of biomarkers.</div></div>","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"233 ","pages":"Article 116132"},"PeriodicalIF":7.1,"publicationDate":"2025-12-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145735789","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Recent treatment and survival trends in older versus younger women with HR-positive HER2-negative metastatic breast cancer in the real-life multicenter French ESME cohort","authors":"Fanny Bouteiller ,&nbsp;Sophie Gourgou ,&nbsp;Michaël Bringuier ,&nbsp;Angéline Galvin ,&nbsp;Audrey Mailliez ,&nbsp;Nicolas Bertrand ,&nbsp;Mony Hung ,&nbsp;Jean-Sébastien Frenel ,&nbsp;Vincent Massard ,&nbsp;Thomas Bachelot ,&nbsp;Carole Pflumio ,&nbsp;Anthony Gonçalves ,&nbsp;Christelle Levy ,&nbsp;Lise Bosquet ,&nbsp;William Jacot ,&nbsp;Suzette Delaloge ,&nbsp;Thomas Grinda ,&nbsp;Carine Bellera","doi":"10.1016/j.ejca.2025.116166","DOIUrl":"10.1016/j.ejca.2025.116166","url":null,"abstract":"<div><h3>Aim</h3><div>To describe first-line treatments, overall (OS) and real-world progression-free (rwPFS) survival in women with hormone receptor-positive, HER2-negative (HR+/HER2-) metastatic breast cancer (mBC) following introduction of CDK4/6 inhibitors (CDK4/6i), according to age (&lt;70; 70 +) and diagnostic period (before/after CDK4/6i).</div></div><div><h3>Methods</h3><div>We extracted data from the ESME database (NCT03275311) which includes consecutive patients starting first-line mBC in one of the 18 French Comprehensive cancer centres.</div></div><div><h3>Results</h3><div>We identified 17,830 eligible women (median age: 62 years). Women aged ≥ 70 years were less likely to present with aggressive disease characteristics. Use of endocrine therapy combined with CDK4/6i increased substantially over time in both age groups, from 0.9 % to 48.9 % in 70 + women, and from 0.8 % to 50.1 % in women &lt; 70 (<em>p</em> &lt; 0.001 for both). In contrast, first-line chemotherapy (alone or in combination) declined from 52.7 % to 30.0 % (<em>p</em> &lt; 0.001), with consistently lower use among women 70 + compared to those &lt; 70: 32.2 % vs. 61.1 % prior to 2016, and 16.4 % vs. 36.5 % after 2017 (<em>p</em> &lt; 0.001 for both). Among 70 + women, OS improved over time (34.0–37.3 months, <em>p</em> = 0.03) but remained shorter than in younger women. rwPFS improved in both age groups: from 12.6 to 14.8 months in 70 + women, and from 12.3 to 14.4 months in women &lt; 70 (<em>p</em> &lt; 0.001 for both).</div></div><div><h3>Conclusion</h3><div>ET+CDK4/6i use rose up to ∼50 % after 2017, reaching ∼70 % in recent years among women with good PS, but remained ∼50 % in older patients with poor PS. Broader adoption is needed, with less chemotherapy use. Survival outcomes have improved but, causality cannot be confirmed due to the observational design.</div></div>","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"233 ","pages":"Article 116166"},"PeriodicalIF":7.1,"publicationDate":"2025-12-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145780443","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Liposomal irinotecan in patients with HER2-negative breast cancer and brain metastases: The PHENOMENAL phase 2 study","authors":"Manuel Ruiz Borrego ,&nbsp;David Páez López-Bravo ,&nbsp;Mireia Margelí Vila ,&nbsp;José Manuel Pérez-García ,&nbsp;María Fernández ,&nbsp;Salvador Blanch Tormo ,&nbsp;José Ángel García-Saenz ,&nbsp;Laura Lema ,&nbsp;Isabel Garau ,&nbsp;Patricia Cortez ,&nbsp;Antonio Antón Torres ,&nbsp;Emilio Alba Conejo ,&nbsp;Isabel Calvo ,&nbsp;Neus Ferrer ,&nbsp;Isabel Blancas ,&nbsp;Kepa Amillano ,&nbsp;Sandra Santasusagna ,&nbsp;Marc Antoine Benderra ,&nbsp;Daniel Alcalá-López ,&nbsp;Gabriele Antonarelli ,&nbsp;Javier Cortés","doi":"10.1016/j.ejca.2025.116161","DOIUrl":"10.1016/j.ejca.2025.116161","url":null,"abstract":"<div><h3>Introduction</h3><div>Patients with breast cancer (BC) and brain metastases (BMs) have a poor prognosis, particularly those with human epidermal growth factor 2-negative (HER2[-]) BC, including hormone receptor-positive (HR[+]) and triple-negative breast cancer (TNBC). Liposomal irinotecan (nal-IRI) crosses the blood-brain barrier and enhances antitumor activity.</div></div><div><h3>Methods</h3><div>PHENOMENAL (NCT03328884) was a single-arm, open-label, multicenter phase 2a study in Spain. Eligible patients had HER2[-] BC with active or stable BMs and prior chemotherapy regimen for metastatic disease (≥1 taxane line required). Nal-IRI was administered intravenously at 60 mg/m² (salt-base) or 50 mg/m² (free-base) every 14 days until progression and/or unacceptable toxicity. The primary endpoint was intracranial objective response rate (IC-ORR) in patients with progressive BMs. Key secondary endpoints included ORR, clinical benefit rate (CBR), progression-free survival (PFS), overall survival (OS), and safety.</div></div><div><h3>Results</h3><div>Fifty-six women (median age 52 years; range, 32–83) were enrolled across 16 sites. Of these, 51.8 % had TNBC, and 91.1 % had progressive BMs at baseline. Median follow-up was 5.7 months (range, 0.4–56.5). The trial achieved its primary endpoint, with IC-ORR of 22.0 % (95 % CI, 11.5–36.0; <em>p</em> &lt; 0.001) among patients with progressive BMs. Median PFS was 1.5 months (95 % CI, 1.4–2.9), while median OS reached 6.4 months (95 % CI, 4.9–10.8).</div><div>Treatment-emergent adverse events (TEAEs) occurred in 96.4 % of patients; 57.1 % were considered treatment-related and 14.3 % experienced grade ≥ 3 treatment-related events. Only one patient had a serious treatment-related event, and no treatment-related deaths occurred.</div></div><div><h3>Conclusions</h3><div>nal-IRI demonstrated IC activity in HER2[-] BC with BMs. While overall efficacy was limited and long-term outcomes remain poor, these results highlight the unmet need in this challenging population and support the importance of developing more treatment strategies.</div></div>","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"233 ","pages":"Article 116161"},"PeriodicalIF":7.1,"publicationDate":"2025-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145721844","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Letter to the editor Re: Immunotherapy and PARP inhibitors as first-line treatment in endometrial cancer: A systematic review and network meta-analysis","authors":"Yibin Lin ,&nbsp;Xiao Chen ,&nbsp;Wei Chen,&nbsp;Yang Sun","doi":"10.1016/j.ejca.2025.116163","DOIUrl":"10.1016/j.ejca.2025.116163","url":null,"abstract":"","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"233 ","pages":"Article 116163"},"PeriodicalIF":7.1,"publicationDate":"2025-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145735855","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Response to letter Re: Tarlatamab-induced immune-related adverse events: Real-world pharmacovigilance study using the FAERS database","authors":"Nikhil Vojjala,&nbsp;Prakash Neupane,&nbsp;Nausheen Ahmed","doi":"10.1016/j.ejca.2025.116151","DOIUrl":"10.1016/j.ejca.2025.116151","url":null,"abstract":"","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"233 ","pages":"Article 116151"},"PeriodicalIF":7.1,"publicationDate":"2025-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145693228","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The telomerase vaccine UV1 combined with ipilimumab and nivolumab versus ipilimumab and nivolumab in advanced melanoma (INITIUM): A randomized open-label phase 2 study","authors":"Paul Lorigan ,&nbsp;Theresa Michelle Medina ,&nbsp;Marta Nyakas ,&nbsp;Annemie Rutten ,&nbsp;Lynn G. Feun ,&nbsp;Charles Lance Cowey ,&nbsp;Miranda Payne ,&nbsp;Israr Hussain ,&nbsp;Timothy Kuzel ,&nbsp;Steven O’Day ,&nbsp;Amna Sheri ,&nbsp;Philip Adam Friedlander ,&nbsp;Satish Kumar ,&nbsp;Vanja Sue Bergersen ,&nbsp;Øivind Foss ,&nbsp;Espen Basmo Ellingsen ,&nbsp;Jens Bjørheim ,&nbsp;Oliver Edgar Bechter","doi":"10.1016/j.ejca.2025.116162","DOIUrl":"10.1016/j.ejca.2025.116162","url":null,"abstract":"<div><h3>Purpose</h3><div>Immune checkpoint inhibitor (ICI) combinations have improved outcomes in patients with advanced melanoma; however, long term survival remains poor. The addition of therapeutic cancer vaccines to ICI combinations represents a promising strategy to enhance efficacy.</div></div><div><h3>Methods</h3><div>In this phase 2, randomized, open-label trial, 156 patients with unresectable or metastatic melanoma were randomized 1:1 to receive 4 cycles of ipilimumab 3mg/kg and nivolumab 1mg/kg with or without UV1, a telomerase-targeted therapeutic cancer vaccine, followed by maintenance nivolumab 480 mg every 4 weeks. The primary endpoint was progression-free survival (PFS) based on blinded independent central review. Secondary endpoints included overall survival (OS), response assessments, and safety.</div></div><div><h3>Results</h3><div>At a minimum follow-up of 18 months, the projected median PFS was 34.3 months (95 % confidence interval [CI], 7.95 to NR) with ipilimumab-nivolumab-UV1 and 38.4 months (95 % CI, 8.15–38.37) with ipilimumab-nivolumab (hazard ratio, 0.95 [95 % CI, 0.59–1.55]). PFS at 12 months was 57 % (95 % CI, 45.0–68.1) and 57 % (95 % CI, 44.6–67.0) in the ipilimumab-nivolumab-UV1 and ipilimumab-nivolumab arms, respectively. Objective response rates were 59.7 % (ipilimumab-nivolumab-UV1) and 59.2 % (ipilimumab-nivolumab; odds ratio, 1.12; 95 % CI, 0.58–2.16). Median overall survival was not reached in either arm (hazard ratio, 1.15 [95 % CI, 0.60–2.20]). Grade &gt; 3 treatment-emergent adverse events were reported in 64.5 % and 65.4 % of patients respectively.</div></div><div><h3>Conclusion</h3><div>For patients with treatment naïve advanced melanoma, the addition of UV1 to ipilimumab-nivolumab did not result in improved efficacy compared with ipilimumab-nivolumab alone.</div></div>","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"233 ","pages":"Article 116162"},"PeriodicalIF":7.1,"publicationDate":"2025-12-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145713863","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Large B-cell lymphoma: The LYSA pragmatic guidelines","authors":"Pierre Sesques ,&nbsp;Guillaume Manson ,&nbsp;Sydney Dubois ,&nbsp;Francois Xavier Gros ,&nbsp;Gabriel Brisou ,&nbsp;Clémentine Sarkozy ,&nbsp;Sophie Bernard ,&nbsp;Estelle Bourbon ,&nbsp;Luc Matthieu Fornecker ,&nbsp;Eric Durot ,&nbsp;Laurent Martin ,&nbsp;Catherine Chassagne-Clément ,&nbsp;Francisco Llamas Gutierrez ,&nbsp;Charlotte Syrykh ,&nbsp;Marie-Hélène Delfau-Larue ,&nbsp;Salim Kanoun ,&nbsp;Laetitia Vercellino ,&nbsp;Caroline Bodet-Milin ,&nbsp;Haifa Bahri ,&nbsp;Jules Zhang Yin ,&nbsp;Benoit Tessoulin","doi":"10.1016/j.ejca.2025.116070","DOIUrl":"10.1016/j.ejca.2025.116070","url":null,"abstract":"<div><div>The management of large B-cell lymphomas (LBCL) has undergone major changes over the last 5 years. These changes reflect the availability of new therapies (immunotherapies, cell therapies, targeted molecules), but also a better compartmentalization of the entities and their specific clinical characteristics. Numerous first-, second- and third-line therapeutic strategies are available, and each practitioner is committed to selecting the treatment that offers the best balance between efficacy and toxicity. Advances in the understanding of LBCL biology, coupled with improvements in diagnostic and monitoring tools and therapeutic approaches, have significantly enhanced patient outcomes in recent years. In this article, we present a set of pragmatic guidelines developed by the LYSA (Lymphoma Study Association) for the management of LBCL. These guidelines address key aspects of diagnosis, staging, response evaluation, and treatment, integrating the latest evidence from clinical trials, expert consensus, and real-world practice. They aim to provide clinicians with a clear, practical framework to optimize care for patients with LBCL, ensuring that the best available evidence is translated into clinical practice.</div></div>","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"232 ","pages":"Article 116070"},"PeriodicalIF":7.1,"publicationDate":"2025-12-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145681641","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Subsequent anticancer therapy in patients randomized to placebo alone or best supportive care","authors":"Christopher Rios ,&nbsp;Alyson Haslam ,&nbsp;Timothée Olivier","doi":"10.1016/j.ejca.2025.116148","DOIUrl":"10.1016/j.ejca.2025.116148","url":null,"abstract":"<div><h3>Aim</h3><div>Oncology randomized controlled trials (RCTs) may use placebo or best supportive care (BSC) as control arms under certain conditions. The appropriateness of such comparators is uncertain when many control patients subsequently receive anticancer therapy. This study aimed to evaluate whether the use of inert control arms in recent FDA registration trials was justified, using subsequent anticancer therapy data.</div></div><div><h3>Methods</h3><div>We conducted a cross-sectional analysis of FDA registration trials for anticancer drugs approved between January 2009 and November 2024, identified from an internally compiled database of FDA records. Eligible trials were RCTs in advanced or metastatic disease using placebo-only or BSC as the control arm and reporting subsequent systemic therapy for at least the control group. Data on trial characteristics, crossover design, subsequent therapy, and outcomes were abstracted. Descriptive statistics and regression analyses assessed associations between subsequent therapy rates and trial outcomes.</div></div><div><h3>Results</h3><div>Among 550 FDA approvals, 18 trials met inclusion criteria. Overall, 49 % of patients in control arms received subsequent systemic therapy. Trials allowing crossover reported higher rates of subsequent therapy (66.0 %) than those without crossover (40.7 %). A significant inverse association was observed, with a 0.07 decrease in hazard ratio for every 10 % increase in control patients receiving subsequent therapy.</div></div><div><h3>Conclusion</h3><div>Nearly half of patients in control arms of trials using inert comparators received subsequent active therapy, calling into question the appropriateness of these control designs. Inappropriate use of inactive controls may inflate treatment effects. Regulators and ethics committees should ensure justified comparator selection in vulnerable populations.</div></div>","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"233 ","pages":"Article 116148"},"PeriodicalIF":7.1,"publicationDate":"2025-12-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145735721","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Letter Re: Tarlatamab-induced immune-related adverse events: Real-world pharmacovigilance study using the FAERS database","authors":"Emanuel Raschi ,&nbsp;Charles Khouri ,&nbsp;Elisabetta Poluzzi,&nbsp;Fabrizio De Ponti","doi":"10.1016/j.ejca.2025.116150","DOIUrl":"10.1016/j.ejca.2025.116150","url":null,"abstract":"","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"232 ","pages":"Article 116150"},"PeriodicalIF":7.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145681553","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}